42,990 Shares in ProKidney Corp. (NASDAQ:PROK) Bought by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new stake in ProKidney Corp. (NASDAQ:PROK) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,990 shares of the company’s stock, valued at approximately $106,000.

Several other institutional investors and hedge funds have also bought and sold shares of PROK. The Manufacturers Life Insurance Company bought a new position in shares of ProKidney in the 2nd quarter worth approximately $60,000. AQR Capital Management LLC purchased a new stake in ProKidney during the second quarter valued at approximately $50,000. Marshall Wace LLP purchased a new stake in ProKidney during the second quarter valued at approximately $124,000. Rhumbline Advisers raised its position in ProKidney by 8.8% in the second quarter. Rhumbline Advisers now owns 76,190 shares of the company’s stock worth $187,000 after acquiring an additional 6,181 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of ProKidney by 44.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company’s stock worth $441,000 after acquiring an additional 55,266 shares during the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.

ProKidney Stock Performance

Shares of PROK stock opened at $1.70 on Friday. The stock has a fifty day simple moving average of $2.20 and a two-hundred day simple moving average of $2.40. The firm has a market capitalization of $388.74 million, a PE ratio of -2.97 and a beta of 1.08. ProKidney Corp. has a 52-week low of $1.12 and a 52-week high of $4.85.

ProKidney (NASDAQ:PROK) last released its earnings results on Friday, August 9th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. On average, sell-side analysts forecast that ProKidney Corp. will post -0.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Bank of America reduced their price objective on ProKidney from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group reduced their price target on ProKidney from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, June 10th. JPMorgan Chase & Co. started coverage on ProKidney in a research report on Monday, September 30th. They set a “neutral” rating on the stock. Finally, Guggenheim initiated coverage on shares of ProKidney in a report on Tuesday, September 10th. They issued a “buy” rating and a $6.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.50.

Insider Activity

In related news, insider Darin J. Weber sold 16,412 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $2.50, for a total transaction of $41,030.00. Following the completion of the transaction, the insider now owns 103,480 shares in the company, valued at approximately $258,700. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 41.49% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.